Company news

AstraZeneca PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Forxiga approved in China for CKD

September 5, 2022

Imfinzi approved in US for biliary tract cancer

September 5, 2022

Evusheld approved for COVID-19 in Japan

August 30, 2022

Farxiga shows CV mortality benefit across EF range

August 30, 2022

Farxiga reduced risk of CV death or worsening HF

August 30, 2022

Ultomiris approved in Japan for gMG

August 25, 2022

Tagrisso approved in Japan for early lung cancer

August 25, 2022

Lynparza approved in Japan for early breast cancer

August 25, 2022

Lynparza granted FDA priority review for PROpel

August 16, 2022

Enhertu improved PFS in mBC in DESTINY-Breast02

August 15, 2022

Enhertu approved in US for HER2-mutant NSCLC

August 12, 2022

Acquisition of TeneoTwo completed

August 11, 2022

Enhertu approved in the US for HER2-low mBC

August 8, 2022

Lynparza approved in EU for early breast cancer

August 4, 2022

Chair succession

July 29, 2022

Tezspire recommended for EU approval in asthma

July 25, 2022

Ultomiris recommended for EU approval for gMG

July 25, 2022

Enhertu granted Priority Review for HER2-low mBC

July 25, 2022

Enhertu approved in EU for HER2-positive mBC

July 19, 2022

AstraZeneca to acquire TeneoTwo and T cell engager

July 5, 2022

Imfinzi improved pCR in resectable lung cancer

June 30, 2022

Enhertu recommended for breast cancer EU approval

June 27, 2022

Lynparza recommended in EU for early breast cancer

June 27, 2022

Eplontersen Ph III trial met co-primary endpoints

June 21, 2022

Enhertu efficacy results in HER2-low breast cancer

June 6, 2022

Appointment of joint corporate brokers

May 9, 2022

Enhertu approved in US for 2L HER2+ breast cancer

May 5, 2022

Farxiga HFpEF Phase III trial met primary endpoint

May 5, 2022

Ultomiris NMOSD Ph. III trial met primary endpoint

May 5, 2022

Imfinzi combo granted Priority Review for BTC

May 4, 2022

AstraZeneca plans new R&D centre in Massachusetts

April 29, 2022

First quarter 2022 results

April 29, 2022

Ultomiris approved in the US for adults with gMG

April 28, 2022

Enhertu granted BTD for HER2-low breast cancer

April 27, 2022

Tremelimumab US Priority Review for Imfinzi combo

April 25, 2022

Enhertu granted Priority Review for HER2m NSCLC

April 19, 2022

Ondexxya approved in Japan for FXai reversal

March 29, 2022

Evusheld approved in the EU for COVID-19

March 28, 2022

Evusheld Positive EU CHMP Opinion

March 24, 2022

Update on CALLA Phase III trial for Imfinzi

March 24, 2022

Settlement of patent litigation for Ultomiris

March 17, 2022

Lynparza approved in US for early breast cancer

March 14, 2022

Update on US review of Fasenra in nasal polyps

March 14, 2022

AstraZeneca and Neurimmune close deal for NI006

March 1, 2022

Chair succession planning update and Annual Report

February 22, 2022

Enhertu improves PFS and OS in HER2-low BC

February 21, 2022

Saphnelo approved in EU for SLE

February 16, 2022

Lynparza combo delays progression risk in prostate

February 15, 2022

AZN: Full year and Q4 2021 results

February 10, 2022

Imfinzi improves survival in biliary tract cancer

January 19, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 249 decks. Every deck is listed under its year.